Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody i-131-CC49

Lale Kostakoglu, Chaitanya R. Divgi, Susan Hilton, Carlos Cordon-Cardo, Andrew M. Scott, Hovanes Kalaigian, Ronald D. Finn, Jeffrey Schlom, Steven M. Larson

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

We studied 18 consecutive patients with advanced colorectal cancer where primary tumors were preselected for high expression of TAG-72 antigen and who underwent a phase I radioimmunotherapy trial with an intravenously administered monoclonal antibody CC49, 20 mg, labeled with 1-131 in amounts varying from 15 mCi/m2 to 75 mCi/m2. Whole-body images and SPECT of the abdomen obtained I week after infusion were compared with pretreatment CT scans. A total of 66 lesions were evaluated. SPECT revealed 2/66 lesions (3% that were not detected by CT; 4/66 were only detected by CT: lungs (1.8 cm and <1 cm), axilla (1.5 cm), adrenal (2.5 cm). Thus, based on immunohistopathological testing in paraffin-embedded tissue blocks of primary tumors stained for TAG-72 antigen, we have selected a subset of patients (about 70% of referrals) with colorectal cancer for whom I-131-CC49 was shown to target to 62/64 CT positive lesions (97% and 62/66 (94% of all known positive lesions. We conclude that in patients with significant TAG-72 tumor expression there is excellent targeting of 1-131-CC49 in therapeutic doses to colorectal cancer with respect to lesions detected with CT scanning. It should be noted that this study was not designed as a comparison of the sensitivity of CT versus 1-131-CC49 SPECT/planar imaging. Instead, the observed results are consistent with a biological hypothesis that in general, the primary tumor histology vis-a-vis TAG-72 expression reflects the TAG-72 expression of the metastatic sites.

Original languageEnglish
Pages (from-to)551-558
Number of pages8
JournalCancer Investigation
Volume12
Issue number6
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Dive into the research topics of 'Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody i-131-CC49'. Together they form a unique fingerprint.

Cite this